Enzymotec Ltd. (NASDAQ:ENZY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, ValuEngine upgraded Enzymotec from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Four analysts have rated the stock with a hold rating, The company currently has a consensus rating of “Hold” and an average price target of $8.00.
Enzymotec (ENZY) traded up 1.37% during trading on Tuesday, hitting $11.10. The stock had a trading volume of 18,025 shares. Enzymotec has a 1-year low of $5.20 and a 1-year high of $12.35. The firm’s market cap is $254.73 million. The firm’s 50 day moving average is $11.38 and its 200 day moving average is $9.25.
Enzymotec (NASDAQ:ENZY) last issued its earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.15). Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The firm had revenue of $13.00 million during the quarter, compared to analysts’ expectations of $12.78 million. During the same quarter last year, the firm earned $0.04 EPS. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. On average, analysts anticipate that Enzymotec will post $0.14 earnings per share for the current year.
WARNING: This news story was posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/10/18/enzymotec-ltd-enzy-upgraded-to-hold-at-zacks-investment-research.html.
A number of hedge funds and other institutional investors have recently modified their holdings of ENZY. Janus Henderson Group PLC purchased a new position in Enzymotec in the second quarter valued at about $2,350,000. Osborn Williams & Donohoe LLC purchased a new position in Enzymotec in the third quarter valued at about $137,000. Finally, State Street Corp grew its stake in Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 380 shares in the last quarter. Hedge funds and other institutional investors own 27.98% of the company’s stock.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.